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Background: Work problems are common in people with inflammatory arthritis (IA): with 28-40% of 
people with rheumatoid arthritis (RA) stopping work in 5y of diagnosis. There is little research into 
effectiveness of job retention vocational rehabilitation (JR-VR) for employed people with IA. Brief JR-
VR led to significantly fewer job losses at 3.5 years in the USA (Allaire et al, 2003) and a UK pilot trial 
demonstrated 6m improvements in work instability and work satisfaction (Macedo et al, 2009).  
Objectives:  To conduct a pilot randomised controlled trial (RCT) evaluating a JR-VR intervention with 
employed people with IA, to facilitate planning a full RCT.  
Method: Participants with IA were recruited from 6 Rheumatology departments and randomised to VR 
(delivered by Rheumatology OTs with VR training) or a control group. Both groups received written 
self-help information about managing work problems. The VR group could receive up to 6h JR-VR, 
including a work visit. Presenteeism outcomes included: RA-Work Instability Scale (RAWIS:0-23), 
Work Limitations Questionnaire Productivity Loss (WLQPL: %), Work Activities Limitations Scale 
(WALS:0-33). Absenteeism was measured using monthly work diaries. Health outcomes included: 
SF12v2 Physical component (SF12-PC), pain and fatigue VAS (0-100). Mean (SD) change scores 
and effect sizes were calculated. 
Results: 213 eligible employed patients with IA were identified, of whom 55 (26%) participated (34 
with RA): 13M, 42F; aged 49y (SD 8.8); 7.9y (SD 8.9) disease duration; 33 worked full-time; job types 
were professional (27%), associated professional/skilled (15%), partly skilled/admin/caring/retain 
(53%), unskilled (5%). Both groups were comparable at baseline (see Table). At 9m: effect 
sizes were moderate to large for changes in work and health outcomes in the JR-VR group and none 
to small in the control group; %working days lost due to sickness: JR-VR =9.6% (SD 13.6); control = 
20% (SD 27.1). JR-VR lasted on average 3.08 (SD 1.8) hours and cost £74.98 (SD £46.80) per 
patient. 








RAWIS 16.2 (5) -3.9 (5.3) -0.74 15 (5.7) -1 (3.5) -0.19 
WLQPL 10.9 (4.9) -3.2 (3.7) -0.62 11.2 (5.6) -0.4 (4.3) -0.08 
WALS 12.8 (5.3) -2.2 (4.5) -0.39 12.7 (6.2) 0.6 (6.0) 0.11 
SF12PC 32.5 (8.3) 5.3 (11.11) 0.58 32.6 (10.1) 2.5 (8.3) 0.27 
Pain 50.4 (22.6) -12 (27) -0.50 45.7 (25.7) 0.1 (21.8) 0 
Fatigue 60 (22.4) -5.3 (22.9) -0.20 58.7 (30.1) 5.4 (26.4) 0.21 
Health 50.9 (18.4) -14.6 (28.8) -0.71 48.7 (23.1) -3.9 (15.8) -0.19 
 
Conclusions: This pilot suggests brief JR-VR provided by Rheumatology OTs can improve 
presenteeism, absenteeism and health status, indicating a RCT is warranted. Recruitment was 
problematic, with many not consenting. Potential reasons include: fear about employers (in a 
recession) learning they have arthritis; concerns about time out of work attending VR; and not 
perceiving VR is needed as yet. JR-VR intends to prevent work problems. Support is needed to 
enable employed people with IA and work problems to attend JR-VR. 
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